Extremely Robust Acute Respiratory Distress Syndrome Pipeline Featuring 100+ Companies Expected to Change the Pace of the ARDS Treatment | DelveInsight
The acute respiratory distress syndrome (ARDS) pipeline is experiencing substantial growth, with over 100 active players working on 105 pipeline therapies. The increase in ARDS incidence is driving research and development in this sector, making it a lucrative market for new treatments. Companies like Biocon, NRx Pharmaceuticals, and Veru Healthcare are at the forefront of this effort, focusing on innovative therapies such as Itolizumab and Lenzilumab. Notably, Tetra Bio-Pharma secured $150,000 in funding for its ARDS-003 oral formulation development. The report highlights diverse therapeutic approaches, including cell replacements and targeted pharmacological agents.
- Over 100 active companies developing 105+ therapies for ARDS.
- Increased funding for ARDS treatment projects, exemplified by Tetra Bio-Pharma's $150,000 funding.
- Focus on innovative therapies such as Itolizumab and Lenzilumab from leading firms.
- None.
The rise in the incidence of ARDS stimulates the research and development of the drug, as it is likely to provide an appropriate environment for newer products to be profitable. Companies across the globe have shifted their focus toward the treatment of ARDS. The increase in the incidence will potentiate the treatment market for ARDS. Treatment goals, such as "permissive atelectasis", "permissive hypercapnia", and even "permissive hypoxemia", have been introduced as targets of ventilatory support. Together with the increased knowledge and understanding of how mechanical ventilation can harm the lungs, a major effort has been put into preventing or shortening the use of mechanical ventilation as much as possible and using settings that are considered to be "lung-protective." Several other supportive care options are available, but they all do not withstand the current needs of patients for this indication.
Key Takeaways from the Acute Respiratory Distress Syndrome Pipeline Report
- DelveInsight's acute respiratory distress syndrome pipeline report depicts a robust space with 100+ active players working to develop 105+ pipeline therapies for acute respiratory distress syndrome treatment.
- Key acute respiratory distress syndrome companies such as Biocon, NRx Pharmaceuticals, Humanigen, Mesoblast, Sage Therapeutics, Evgen Pharma,
Dimerix Bioscience , Vanda Pharmaceuticals, EUSA Pharma,Veru Healthcare , Foresee Pharmaceuticals,BioMarck Pharmaceuticals ,Boehringer Ingelheim ,Biohaven Pharmaceuticals , Biophytis,NovImmune SA , Constant Therapeutics, Windtree Therapeutics, Acticor Biotech, Direct Biologics, F4 Pharma, Apeiron Biologics, Trevena, Synact Pharma, Pluristem Therapeutics, UCB Pharma,Chiesi Farmaceutici , and others are evaluating new acute respiratory distress syndrome drugs to improve the treatment landscape. - Promising acute respiratory distress syndrome pipeline therapies in various stages of development include Itolizumab, ZYESAMI, Lenzilumab, Remestemcel-L, Brexanolone, SFX-01, DMX-200, Tradipitant, Siltuximab, VERU 111, BIO 11006, FP025, Alteplase, Sarconeos Zavegepant, EB 05, USB 002, Sinapultide, Glenzocimab, DB 001, FX06, APN01, TRV 027, AP1189, PLX PAD, Zilucoplan,
CHF5633 , and others. - In
March 2023 , Tetra Bio-Pharma received up to$150,000 National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a research and development project to enable the development of its ARDS-003 oral formulation. Specifically, the funds will be used to optimize the formulation and perform animal non-GLP Pharmacokinetic Studies. - In
February 2021 , Avid Bioservices and Humanigen announced that they had entered into a manufacturing services agreement to expand production capacity for lenzilumab. Under the terms of this Current Good Manufacturing Practice (cGMP) agreement, Avid would initiate technical transfer and analytical validation activities for lenzilumab with the goal of delivering cGMP drug substance batches to support Humanigen's regulatory and potential commercial activities.
Request a sample and discover the recent advances in ARDS drug treatment @ Acute Respiratory Distress Syndrome Pipeline Report
The acute respiratory distress syndrome pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage acute respiratory distress syndrome drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the acute respiratory distress syndrome clinical trial landscape.
Acute Respiratory Distress Syndrome Overview
Acute respiratory distress syndrome (ARDS) is a rapidly progressing condition that primarily affects the critically ill. The most serious complication of ARDS is fluid leaking into the lungs, making breathing difficult or impossible. The ARDS causes are classified as direct or indirect lung injuries. Direct lung injuries include pneumonia, aspiration, trauma, and others. Examples of indirect lung injuries include pancreatic inflammation, severe infection (also known as sepsis), blood transfusions, burns, and pharmaceutical responses.
ARDS symptoms include shortness of breath, coughing, and fever; in some cases, high heart rates and rapid breathing have also been observed. Patients with ARDS may experience chest pain, especially during inhalation, and some may develop blue nails and lips due to drastically reduced oxygen levels in the blood. Mechanical ventilation, stress ulcer and venous thromboembolism prevention, nutritional support, and underlying damage therapy are all part of the acute respiratory distress syndrome treatment.
Find out more about drugs for ARDS @ New Acute Respiratory Distress Syndrome Drugs
A snapshot of the Acute Respiratory Distress Syndrome Pipeline Drugs mentioned in the report:
Drugs | Company | Phase | MoA | RoA |
Remestemcel-L | Mesoblast | Phase III | Cell replacements | Intravenous |
SFX-01 | Evgen Pharma | Phase II/III | Androgen receptor antagonists; Hedgehog protein modulators; Histone deacetylase inhibitors; NF E2 related factor 2 stimulants; Wnt signalling pathway modulators | Oral |
EB05 | Edesa Biotech/ | Phase II/III | Toll-like receptor 4 antagonists | Intravenous |
MultiStem | Athersys/Healios | Phase II/III | Cell replacements | Intravenous |
Alteplase | Phase II/III | Fibrinolytic agents; Plasminogen activator stimulants; Plasminogen activators | Intravenous | |
BIO-11006 | Phase II | Myristoylated alanine-rich C kinase substrate inhibitors | Inhalation | |
Lucinactant | Windtree Therapeutics | Phase II | Cell membrane permeability enhancers | Intratracheal |
Solnatide | Apeptico Forschung und | Phase II | Sodium channel agonists | Inhalation |
Learn more about the emerging acute respiratory distress syndrome pipeline therapies @ ARDS Clinical Trials
Acute Respiratory Distress Syndrome Therapeutics Assessment
The acute respiratory distress syndrome pipeline report proffers an integral view of acute respiratory distress syndrome emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Acute Respiratory Distress Syndrome Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
- Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
- Therapeutics Assessment By Mechanism of Action: Androgen receptor antagonists, Hedgehog protein modulators, Histone deacetylase inhibitors, NF E2 related factor 2 stimulants, Wnt signalling pathway modulators, Cell replacements, Toll-like receptor 4 antagonists, Fibrinolytic agents, Plasminogen activator stimulants, Plasminogen activators, Myristoylated alanine-rich C kinase substrate inhibitors, Cell membrane permeability enhancers, Sodium channel agonists
- Key Acute Respiratory Distress Syndrome Companies: Biocon, NRx Pharmaceuticals, Humanigen, Mesoblast, Sage Therapeutics, Evgen Pharma,
Dimerix Bioscience , Vanda Pharmaceuticals, EUSA Pharma,Veru Healthcare , Foresee Pharmaceuticals,BioMarck Pharmaceuticals ,Boehringer Ingelheim ,Biohaven Pharmaceuticals , Biophytis,NovImmune SA , Constant Therapeutics, Windtree Therapeutics, Acticor Biotech, Direct Biologics, F4 Pharma, Apeiron Biologics, Trevena, Synact Pharma, Pluristem Therapeutics, UCB Pharma,Chiesi Farmaceutici , and others. - Key Acute Respiratory Distress Syndrome Pipeline Therapies: Itolizumab, ZYESAMI, Lenzilumab, Remestemcel-L, Brexanolone, SFX-01, DMX-200, Tradipitant, Siltuximab, VERU 111, BIO 11006, FP025, Alteplase, Sarconeos Zavegepant, EB 05, USB 002, Sinapultide, Glenzocimab, DB 001, FX06, APN01, TRV 027, AP1189, PLX PAD, Zilucoplan,
CHF5633 , and others.
Dive deep into rich insights for new drugs for ARDS treatment; visit @ Acute Respiratory Distress Syndrome Medications
Table of Contents
1. | Acute Respiratory Distress Syndrome Pipeline Report Introduction |
2. | Acute Respiratory Distress Syndrome Pipeline Report Executive Summary |
3. | Acute Respiratory Distress Syndrome Pipeline: Overview |
4. | Analytical Perspective In-depth Commercial Assessment |
5. | Acute Respiratory Distress Syndrome Clinical Trial Therapeutics |
6. | Acute Respiratory Distress Syndrome Pipeline: Late Stage Products (Pre-registration) |
7. | Acute Respiratory Distress Syndrome Pipeline: Late Stage Products (Phase III) |
8. | Acute Respiratory Distress Syndrome Pipeline: Mid Stage Products (Phase II) |
9. | Acute Respiratory Distress Syndrome Pipeline: Early Stage Products (Phase I) |
10. | Acute Respiratory Distress Syndrome Pipeline Therapeutics Assessment |
11. | Inactive Products in the Acute Respiratory Distress Syndrome Pipeline |
12. | Company-University Collaborations (Licensing/Partnering) Analysis |
13. | Key Companies |
14. | Key Products in the Acute Respiratory Distress Syndrome Pipeline |
15. | Unmet Needs |
16. | Market Drivers and Barriers |
17. | Future Perspectives and Conclusion |
18. | Analyst Views |
19. | Appendix |
For further information on the acute respiratory distress syndrome pipeline therapeutics, reach out @ Acute Respiratory Distress Syndrome Drug Treatment
Related Reports
Acute Respiratory Distress Syndrome Market
Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key acute respiratory distress syndrome companies, including Cellular Biomedicine Group, Baylx, Histocell, Cartesian Therapeutics, Cynata Therapeutics, Immunovative Therapies, Orbsen Therapeutics, Celularity, Bonus BioGroup, Diffusion Pharmaceuticals, among others.
Respiratory Distress Syndrome Market
Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key respiratory distress syndrome companies, including
Chronic Obstructive Pulmonary Disease Market
Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key chronic obstructive pulmonary disease companies, including Sanofi,
Asthma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key asthma companies, including GSK, AstraZeneca,
Severe Asthma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key severe asthma companies, including AstraZeneca, Novartis, Sanofi, among others.
Other Trending Reports
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell
Related Healthcare Blogs
Promising Therapies in the ARDS Market
Rising Acute Respiratory Distress Syndrome Prevalence
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading
Connect with us on LinkedIn|Facebook|Twitter
Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:SOURCE
FAQ
What is the current status of the ARDS drug pipeline as of March 2023?
Which companies are leading the ARDS treatment market?
What is the significance of the $150,000 funding for Tetra Bio-Pharma?
What kinds of therapies are being developed for ARDS?
What are the goals for ARDS treatment according to recent reports?
